Azucena Pérez-Cañamás

Azucena Pérez-Cañamás

Auto-generated profile, based on publicly available information

Azucena Pérez-Cañamás

Cellular Neuroscience, Neurodegeneration, Repair, Departments of Neurology and of Neuroscience, Yale University School of Medicine, New Haven, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
JSJoshua Spurrier
Joshua Spurrier
LNLaShae Nicholson
LaShae Nicholson
XFXiaotian T. Fang
Xiaotian T. Fang
ASAustin J. Stoner
Austin J. Stoner
TTTakuya Toyonaga
Takuya Toyonaga
SSStephen M. Strittmatter
Stephen M. Strittmatter
Microglia-mediated synaptic loss contributes to the development of cognitive impairments in Alzheimer’s disease (AD). However, the basis for this immune-mediated attack on synapses remains to be elucidated. Treatment with the metabotropic glutamate receptor 5 (mGluR5) silent allosteric modulator (SAM), BMS-984923, prevents β-amyloid oligomer–induced aberrant synaptic signaling while preserving physiological glutamate response. Here, we show that oral BMS-984923 effectively occupies brain mGluR5 sites visualized by [ 18 F]FPEB positron emission tomography (PET) at doses shown to be safe in rodents and nonhuman primates. In aged mouse models of AD ( APPswe/PS1 Δ E9 overexpressing transgenic and App NL-G-F / hMapt double knock-in), SAM treatment fully restored synaptic density as measured by [ 18 F]SynVesT-1 PET for SV2A and by histology, and the therapeutic benefit persisted after drug washout. Phospho-TAU accumulation in double knock-in mice was also reduced by SAM treatment. Single-nuclei transcriptomics demonstrated that SAM treatment in both models normalized expression patterns to a far greater extent in neurons than glia. Last, treatment prevented synaptic localization of the complement component C1Q and synaptic engulfment in AD mice. Thus, selective modulation of mGluR5 reversed neuronal gene expression changes to protect synapses from damage by microglial mediators in rodents.

21 August 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LSLluís Samaranch
Lluís Samaranch
APAzucena Pérez-Cañamás
Azucena Pérez-Cañamás
BSBeatriz Soto-Huelin
Beatriz Soto-Huelin
VSVivek Sudhakar
Vivek Sudhakar
JJJerónimo Jurado-Arjona
Jerónimo Jurado-Arjona
MLMaria Dolores Ledesma
Maria Dolores Ledesma
Gene therapy for Niemann-Pick type A disease is safe in nonhuman primates and has therapeutic effects in a mouse model.

5 September 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
HTHideyuki Takahashi
Hideyuki Takahashi
APAzucena Perez-Canamas
Azucena Perez-Canamas
CLChris W Lee
Chris W Lee
HYHongping Ye
Hongping Ye
XHXianlin Han
Xianlin Han
SSStephen M. Strittmatter
Stephen M. Strittmatter
TMEM106B is an endolysosomal transmembrane protein not only associated with multiple neurological disorders including frontotemporal dementia, Alzheimer’s disease, and hypomyelinating leukodystrophy but also potentially involved in COVID-19. Additionally, recent studies have identified amyloid fibrils of C-terminal TMEM106B in both aged healthy and neurodegenerative brains. However, so far little is known about physiological functions of TMEM106B in the endolysosome and how TMEM106B is involved in a wide range of human conditions at molecular levels. Here, we performed lipidomic analysis of the brain of TMEM106B-deficient mice. We found that TMEM106B deficiency significantly decreases levels of two major classes of myelin lipids, galactosylceramide and its sulfated derivative sulfatide. Subsequent co-immunoprecipitation assay showed that TMEM106B physically interacts with galactosylceramidase. We also found that galactosylceramidase activity was significantly increased in TMEM106B-deficient brains. Thus, our results suggest that TMEM106B interacts with galactosylceramidase to regulate myelin lipid metabolism and have implications for TMEM106B-associated diseases.